Skip to main navigation Skip to search Skip to main content

Correction: Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4–NDRG1 axis (Cancer Research (2017) 77 (86–99) DOI: 10.1158/0008-5472.CAN-16-1797)

  • Nandini Verma
  • , Anna Katharina Muller
  • , Charu Kothari
  • , Effrosini Panayotopoulou
  • , Amir Kedan
  • , Michael Selitrennik
  • , Gordon B. Mills
  • , Lan K. Nguyen
  • , Sungyoung Shin
  • , Thomas Karn
  • , Uwe Holtrich
  • , Sima Lev

Research output: Contribution to journalComment/debatepeer-review

Abstract

In the original version of this article (1), two instances of inadvertent duplication of crystal violet staining images occurred in Fig. 1D (control shRNA conditions in MDA-MB-468 and BT-20) and in Fig. 1F (0 mmol/L gefitinib control conditions in MDA-468 and BT-20). In addition, the same set of STAT3 Western blot bands was inadvertently duplicated in Fig. 3A (BT-20 and HCC1937). These errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret these errors.

Original languageEnglish (US)
Pages (from-to)362
Number of pages1
JournalCancer Research
Volume80
Issue number2
DOIs
StatePublished - Jan 15 2020

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'Correction: Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4–NDRG1 axis (Cancer Research (2017) 77 (86–99) DOI: 10.1158/0008-5472.CAN-16-1797)'. Together they form a unique fingerprint.

Cite this